Lung (Non Small Cell)

USO 10090 ARQ197-A-U302: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non–Small-Cell Lung Cancer (NSCLC)

USO 09179 Protocol IMCL CP12-0917: An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

USO 10007 Protocol PAZ113758: A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects with metastatic stage IVA and IVB non-squamous NSCLC after induction therapy with carboplatin or cisplatin plus pemetrexed.

USO 10061 Protocol I4T-MC-JVBA (also known as IMCL CP12-1027) A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy

08035 - A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.

ECOG E4508 Phase II Randomized Study of Carboplatin and Paclitaxel in Combination With Cetuximab and/or Cixutumumab in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Please contact the NYOH Research Department for more information on clinical trials at (518) 489-0044 ext. 1239